Key result
Administration of growth factors induced beneficial effects on left ventricular ejection fraction, myocardial perfusion, and end-systolic volume index in early clinical studies.
Why the study?
Most evidence that growth factor signaling promotes heart repair derives from preclinical models, making it crucial to evaluate whether growth factor-based protocols are effective in the clinical setting.
Does the administration of growth factors improve cardiac function and repair in cardiovascular diseases?
Does the administration of growth factors improve cardiac function and repair in cardiovascular diseases?
Answers are grounded in this paper and cite their sources.
Growth factor therapy shows preliminary promise for cardiovascular regeneration, but data from ongoing randomized controlled trials are needed to confirm clinical efficacy.
Novel advances for cardiovascular diseases (CVDs) include regenerative approaches for fibrosis, hypertrophy, and neoangiogenesis. Studies indicate that growth factor (GF) signaling could promote heart repair since most of the evidence is derived from preclinical models. Observational studies have evaluated GF serum/plasma levels as feasible biomarkers for risk stratification of CVDs. Noteworthy, two clinical interventional published studies showed that the administration of growth factors (GFs) induced beneficial effect on left ventricular ejection fraction (LVEF), myocardial perfusion, end-systolic volume index (ESVI). To date, large scale ongoing studies are in Phase I-II and mostly focussed on intramyocardial (IM), intracoronary (IC) or intravenous (IV) administration of vascular endothelial growth factor (VEGF) and fibroblast growth factor-23 (FGF-23) which result in the most investigated GFs in the last 10 years. Future data of ongoing randomized controlled studies will be crucial in understanding whether GF-based protocols could be in a concrete way effective in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Pascale et al. (2020) conducted a review in Cardiovascular diseases. Growth factors was evaluated. Administration of growth factors induced beneficial effects on left ventricular ejection fraction, myocardial perfusion, and end-systolic volume index in early clinical studies.
Synapse has enriched 10 related papers. Consider them for comparative context: